La bourse est fermée
Dow Jones
32 461,53 +224,00 (+0,69 %) Nasdaq
11 782,21 -41,75 (-0,35 %) Nikkei 225
27 476,87 +91,62 (+0,33 %) EUR/USD
1,0798 +0,0034 (+0,31 %) HANG SENG
19 567,69 -347,99 (-1,75 %) Bitcoin EUR
24 998,84 -788,05 (-3,06 %)
Merck & Co., Inc. (MRK.PA)
Paris - Paris Prix différé. Devise en EUR
Ajouter à la liste dynamique
À la clôture : 04:16PM CEST
Chargement du graphique interactif...
- ACCESSWIRE
Moderna and Merck Announce mRNA-4157/V940, an Investigational Personalized mRNA Cancer Vaccine, in Combination with KEYTRUDA(R) (pembrolizumab), Met Primary Efficacy Endpoint in Phase 2b KEYNOTE-942 Trial
Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced that the Phase 2b KEYNOTE-942/mRNA-4157-P201 trial of mRNA-4157/V940, an investigational personalized mRNA cancer vaccine, in combination with KEYTRUDA®, Merck's anti-PD-1 therapy, demonstrated a statistically significant and clinically meaningful
- ACCESSWIRE
Our Partnerships Help Make Vaccines Accessible Worldwide
Providing vaccines to some of the hardest-to-reach places around the world
© 2023 Yahoo. Tous droits réservés.
